Pharmaceutical

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NNC0519-0130?

NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes.

Apr 17, 2024 - 00:00
NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Eli Lilly and ...

Next Article

Risk adjusted net present value: What is the current valuation of Novartis’s XXB...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Federal regulators, scrambling to keep up with AI in health care, team up with industry to set standards

STAT+: Federal regulators, scrambling to keep up with A...

Mar 4, 2024

Clinical development services for clinical trials

Clinical development services for clinical trials

Sep 22, 2024

STAT+: Medicare has a new plan to address drug shortages — but it could backfire

STAT+: Medicare has a new plan to address drug shortage...

Jul 18, 2023